Evidence map›Paper›PMID 39639092›Full record

ArticleScientific reports2024

Bacterial products initiation of alpha-synuclein pathology: an in vitro study.

Octavian Costin Ioghen, Gisela Gaina, Ioana Lambrescu, Emilia Manole, Sevinci Pop, Teodora Maria Niculescu, Oana Mosoia, Laura Cristina Ceafalan, Bogdan Ovidiu Popescu

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Octavian Costin Ioghen"Victor Babeș" National Institute of Pathology, 050096, Bucharest, Romania.
Gisela Gaina"Victor Babeș" National Institute of Pathology, 050096, Bucharest, Romania.
Ioana Lambrescu"Victor Babeș" National Institute of Pathology, 050096, Bucharest, Romania.
Emilia Manole"Victor Babeș" National Institute of Pathology, 050096, Bucharest, Romania.
Sevinci Pop"Victor Babeș" National Institute of Pathology, 050096, Bucharest, Romania.
Teodora Maria Niculescu"Carol Davila" University of Medicine and Pharmacy, 050474, Bucharest, Romania.
Oana Mosoia"Victor Babeș" National Institute of Pathology, 050096, Bucharest, Romania.
Laura Cristina Ceafalan"Victor Babeș" National Institute of Pathology, 050096, Bucharest, Romania. lauraceafalan@yahoo.com.
Bogdan Ovidiu Popescu"Victor Babeș" National Institute of Pathology, 050096, Bucharest, Romania.

Funding

Ministry of Research, Innovation, and Digitalization in Romania 31PFE/30.12.2021
6 · The paper itself

Abstract

Parkinson's Disease (PD) is a prevalent and escalating neurodegenerative disorder with significant societal implications. Despite being considered a proteinopathy, in which the aggregation of α-synuclein is the main pathological change, the intricacies of PD initiation remain elusive. Recent evidence suggests a potential link between gut microbiota and PD initiation, emphasizing the need to explore the effects of microbiota-derived molecules on neuronal cells. In this study, we exposed dopaminergic-differentiated SH-SY5Y cells to microbial molecules such as lipopolysaccharide (LPS), rhamnolipid, curli CsgA and phenol soluble modulin α-1 (PSMα1). We assessed cellular viability, cytotoxicity, growth curves and α-synuclein levels by performing MTS, LDH, real-time impedance readings, qRT-PCR and Western Blot assays respectively. Statistical analysis revealed that rhamnolipid exhibited concentration-dependent effects, reducing viability and inducing cytotoxicity at higher concentrations, increasing α-synuclein mRNA and protein levels with negative effects on cell morphology and adhesion. Furthermore, LPS exposure also increased α-synuclein levels. Curli CsgA and PSMα-1 showed minimal or no changes. Our findings suggest that microbiota-derived molecules, particularly rhamnolipid and LPS, impact dopaminergic neurons by increasing α-synuclein levels. This study highlights the potential involvement of gut microbiota in initiating the upregulation of α-synuclein that may further initiate PD, indicating the complex interplay between microbiota and neuronal cells.

Indexed as

alpha-SynucleinLipopolysaccharidesCell Line, TumorCell SurvivalDopaminergic NeuronsGlycolipidsHumansParkinson Diseasealpha-SynucleinGlycolipidsLipopolysaccharidesrhamnolipidAlpha-synuclein overexpressionCurli CsgALipopolysaccharideMicrobiotaMicrobiota-derived moleculesParkinson’s diseasePhenol soluble modulin α-1Rhamnolipid

Identifiers

PMID39639092
PMCPMC11621565

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.